Technical Analysis for KROS - Keros Therapeutics, Inc.

Grade Last Price % Change Price Change
D 48.02 -3.44% -1.71
KROS closed down 3.44 percent on Thursday, July 18, 2024, on 81 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Aug 5
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Flat Down Up

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
200 DMA Support Bullish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish -3.44%
MACD Bullish Centerline Cross Bullish -3.44%
Upper Bollinger Band Walk Strength -3.44%
Multiple of Ten Bearish Other -3.44%
Overbought Stochastic Strength -3.44%
Upper Bollinger Band Touch Strength -3.44%

   Recent Intraday Alerts

Alert Time
Down 5% about 16 hours ago
Fell Below 200 DMA about 16 hours ago
Down 1 ATR about 16 hours ago
Down 3% about 20 hours ago
Fell Below 50 DMA about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Keros Therapeutics, Inc. Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Disorders Hypertension Hematology Therapeutic Products Anemia Pulmonary Arterial Hypertension Myelodysplastic Syndrome Osteoporosis Syndromes Genodermatoses Skeletal Disorders Molecule Product Bone Disease Thrombocytopenia Myelofibrosis Hematopathology Musculoskeletal Disorders Osteogenesis Imperfecta

Is KROS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 73.0
52 Week Low 27.03
Average Volume 351,192
200-Day Moving Average 47.85
50-Day Moving Average 48.57
20-Day Moving Average 45.65
10-Day Moving Average 46.40
Average True Range 2.38
RSI (14) 52.61
ADX 27.9
+DI 31.07
-DI 28.49
Chandelier Exit (Long, 3 ATRs) 46.54
Chandelier Exit (Short, 3 ATRs) 48.08
Upper Bollinger Bands 51.41
Lower Bollinger Band 39.90
Percent B (%b) 0.71
BandWidth 25.21
MACD Line 0.16
MACD Signal Line -0.82
MACD Histogram 0.9822
Fundamentals Value
Market Cap 1.63 Billion
Num Shares 34 Million
EPS -4.96
Price-to-Earnings (P/E) Ratio -9.68
Price-to-Sales 229097.34
Price-to-Book 6.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.41
Resistance 3 (R3) 53.45 51.69 52.51
Resistance 2 (R2) 51.69 50.32 51.67 52.21
Resistance 1 (R1) 49.86 49.47 48.98 49.82 51.91
Pivot Point 48.10 48.10 47.67 48.08 48.10
Support 1 (S1) 46.27 46.73 45.39 46.23 44.13
Support 2 (S2) 44.51 45.88 44.49 43.83
Support 3 (S3) 42.68 44.51 43.53
Support 4 (S4) 42.64